JenaValve Technology GMBH
This article was originally published in Start Up
JenaValve is developing percutaneous aortic valve replacement technology for high-risk patients with severe aortic stenosis. Its self-expanding heart valve and delivery system offer flexible conduit and secure implantation under beating-heart conditions, and its stent valve positioning system has the unique ability to reposition at any time, which is important for precise placement of the implant.
You may also be interested in...
In heart valve surgery, there have been no home runs yet among the numerous efforts to improve the durability of tissue valves. ValveXchange Inc. has a different solution: improving the way that worn valves are replaced. The start-up is developing a tissue valve with exchangeable leaflets that can be exchanged either percutaneously or via minimally invasive techniques. By focusing on the replacement procedure, ValveXchange aims to make bioprosthetic valves more attractive to the increasingly younger patient population for whom its faster and safer exchange technology will provide a lifetime solution.
In this issue, we present another installment of our quarterly review of medical device and in vitro diagnostics/research dealmaking-for July-September 2007. Our data are derived from Windhover's Strategic Transactions Database.
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Cardiovascular Drug Start-Ups," features profiles of AcelleRX Therapeutics, BioVascular, Nile Therapeutics and VIA Pharmaceuticals. Plus these Start-Ups Across Health Care: JenaValve, Moberg Derma, ProtAffin, and Virtual Ports.